{
  "id": 20241443,
  "title": "Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027",
  "url": "https://urgent.news/2026/11/15/prediction-10-000-equally-split-between-eli-lilly-and-novo-nordisk",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-15T23:30:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/15/prediction-usd10-000-equally-split-between-eli-lilly-and-novo-nordisk-will-be-worth-this-much-by-the-end-of-2027/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "The stock prices of Eli Lilly and Novo Nordisk have been diverging over the past year. While Eli Lilly's shares have risen by 41%, Novo Nordisk's have fallen by 15%. Both pharmaceutical giants are in the lead of the rapidly expanding weight loss drug market, and they both have promising Phase 3 clinical candidates. However, they face potential challenges such as intensified competition in the weight-loss sector.\n\nAssuming equal investment of $10,000 in both stocks, a possible future value of this investment by the end of 2027 can be estimated. For Eli Lilly, the stock's price-to-sales ratio could decrease from its current 14.9 to 14.2, yielding a potential gain of around 10.91%. This would result in a $5,000 investment growing to approximately $5,546.\n\nSimilarly, for Novo Nordisk, the stock's price-to-sales ratio may increase from 3.56 to 4, leading to an expected gain of around 13.67%. This would cause the $5,000 investment in Novo to swell to approximately $5,684.\n\nBased on these projections, if $10,000 were divided equally between Eli Lilly and Novo Nordisk, the combined investment could potentially be worth $11,230 by the end of 2027. However, it's essential to note that there is considerable uncertainty in stock market projections, and any gains should be viewed as a long-term investment rather than a short-term windfall. Nonetheless, based on their strong financial performance and promising pipelines, Eli Lilly and Novo Nordisk remain attractive options for healthcare investors in the long run.",
  "summary": "Hint: It’s not a bad investment idea.",
  "key_points": [
    "Eli Lilly stock up 41% vs Novo Nordisk's 15% decline",
    "Price-to-sales ratio shifts for both stocks projected",
    "Combined $10k investment in both could be worth $11,230 by end of 2027"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}